Targeting Latent Human Cytomegalovirus (CMV) with a Novel Fusion Toxin Protein during Ex Vivo Lung Perfusion

R. VP Ribeiro,T. Ku,V.H. Ferreira, M. Galasso,S. Moshkelgosha, V. Michaelsen, A. Wang,A. Ali,K. Ramadan, B.M. Gomes,L. Pires, H. Gokhale, A. Gazzalle,J. Sinclair, T. Kledal,M. Liu, S. Keshavjee, A. Humar,M. Cypel

JOURNAL OF HEART AND LUNG TRANSPLANTATION（2020）

引用 3|浏览11

暂无评分

摘要

Our study demonstrates that ex vivo F49A-FTP treatment of human lungs on EVLP markedly attenuates CMV reactivation. Ongoing ex vivo and in vivo reactivation experiments will confirm these findings.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要